Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06508983
- Locations
- 🇨🇳
Beijing Chaoyang Hospital of Capital Medical University, Beijing, Beijing, China
🇨🇳Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
SG2918 For Advanced Malignant Tumors
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT06167486
- Locations
- 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Drug: SG301 SC InjectionDrug: SG301 SC Placebo
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06144710
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 122
- Registration Number
- NCT06076291
- Locations
- 🇨🇳
The Affiliated Hospital of USTC, Hefei, Anhui, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Henan Cancer Hospital, Zhenzhou, Henan, China
SG1906 for CLDN18.2-Positive Solid Tumors
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05857332
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital Of Xiamen University, Xiamen, Fujian, China
🇨🇳The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- Prev
- 1
- 2
- Next